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Abstract
Background: Candidiasis is the most common opportunistic infection seen in human immunodeficiency virus
(HIV)-infected individuals. The aim of our study was to estimate the candidiasis rate and evaluate its trend in HIV-
infected children in Spain during the era of highly active antiretroviral therapy (HAART) compared to HIV-uninfected
children.
Methods: We carried out a retrospective study. Data were obtained from the records of the Minimum Basic Data
Set from hospitals in Spain. All HIV-infected children were under 17 years of age, and a group of HIV-uninfected
children with hospital admissions matching the study group by gender and age were randomly selected. The
follow-up period (1997–2008) was divided into three calendar periods: a) From 1997 to 1999 for early-period
HAART; b) from 2000 to 2002 for mid-period HAART; and c) from 2003 to 2008 for late-period HAART.
Results: Among children with hospital admissions, HIV-infected children had much higher values than HIV-
uninfected children during each of the three calendar periods for overall candidiasis rates (150.0 versus 6.1 events
per 1,000 child hospital admissions/year (p < 0.001), 90.3 versus 3.1 (p < 0.001), and 79.3 versus 10.7 (p < 0.001),
respectively) and for non-invasive Candida mycosis (ICM) rates (118.5 versus 3.8 (p < 0.001), 85.3 versus 2.3
(p < 0.001), and 80.6 versus 6.0 (p < 0.001), respectively). In addition, HIV-infected children also had higher values of
ICM rates than HIV-uninfected children, except during the last calendar period when no significant difference was
found (32.4 versus 1.2 (p < 0.001), 11.6 versus 0.4 (p < 0.001), and 4.6 versus 2.3 (p = 0.387), respectively). For all
children living with HIV/AIDS, the overall candidiasis rate (events per 1,000 HIV-infected children/year) decreased
from 1997–1999 to 2000–2002 (18.8 to 10.6; p < 0.001) and from 2000–2002 to 2003–2008 (10.6 to 5.7; p = 0.060).
Within each category of candidiasis, both non-ICM and ICM rates experienced significant decreases from 1997–1999
to 2003–2008 (15.9 to 5.7 (p < 0.001) and 4.1 to 0.3 (p < 0.001), respectively).
Conclusions: Although the candidiasis rate still remains higher than in the general population (from 1997 to 2008),
candidiasis diagnoses have decreased among HIV-infected children throughout the HAART era, and it has ceased to
be a major health problem among children with HIV infection.
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Background
In developed countries, the number of human im-
munodeficiency virus (HIV)-infected children receiving
highly active antiretroviral therapy (HAART) has in-
creased since 1996. During its earliest years, HAART
had important limitations such as only a few approved
pediatric formulations of protease inhibitor (PI), diffi-
culties with administration and low adherence, as well
as issues with unsuitable formulations and inadequate
pharmacokinetics [1-3]. The introduction of new drugs
and formulations after 1999 [4,5] extended the use of
HAART to a larger number of children [6]. And after
2002, new HAART regimens allowed for increased ad-
herence and effectiveness [7].
In the pre-HAART era, opportunistic infections were
the primary cause of death in HIV-infected children
[8,9]. Current HAART regimens work by achieving
maximal viral load suppression and increasing CD4+ T-
cell (CD4+) counts [10], and have resulted in a substantial
and dramatic decrease in acquired immunodeficiency syn-
drome (AIDS)-related opportunistic infections, morbid-
ity, hospitalizations and deaths in HIV-infected children
[8,11-15].
Candidiasis is the most common opportunistic infec-
tion seen in HIV-infected children, particularly in HIV-
infected children with persistently low CD4+ counts
[16]. Localized disease caused by Candida is character-
ized by limited tissue invasion in the skin or mucosa.
Once the organism penetrates the mucosal sur-
face and widespread hematogenous dissemination oc-
curs, invasive Candida mycosis (ICM) ensues [17]. ICM
usually occurs in critical situations with advanced stages of
immune-suppression [16], and it has proved to be a signifi-
cant cause of morbidity in HIV-infected patients during the
course of hospitalization [17]. However, the impact of
HAART has resulted in a decline in the incidence of can-
didiasis in this population [11,14,18]. Candida-specific im-
munity is one of the earliest to recover in response to
HAART, which is consistent with increases in CD4+ counts
and the disappearance of clinical signs in response to
HAART [19,20].
The aim of our study was to estimate the candidiasis
rate and evaluate its trend in HIV-infected children




We carried out a retrospective study from 1997 to 2008
among all HIV-infected children under 17 years of age
with a hospital admission in Spain (Figure 1) [21]. In
addition, we selected a control group composed of 4
HIV-uninfected children for each HIV-infected child
studied. This control group (selective ‘cohort’ which
has not been exposed to HIV or HAART) was ran-
domly selected from all HIV-uninfected children under
17 with hospital admissions and matched by gender
and age.
Data were obtained from the records of the Minimum
Basic Data Set (MBDS) of hospitals in Spain, as we pre-
viously described [21]. The MBDS is a database that
captures 97.7% of all public hospital admissions and
25% of all private hospital admissions in Spain. We did
not have data permitting us to estimate the proportion
of HIV-infected children in Spain who received care at
a private hospital. However, all HIV-infected children
are treated through the public health system in Spain
and, thus, would be likely to receive their care at public
hospitals. The MBDS system showed no significant var-
iations during the whole study period (1997–2008).
Data were treated with full confidentiality, according
to Spanish legislation. Patient identifiers were deleted
before the database was provided to the authors in
order to keep strict patient confidentiality. It is not pos-
sible to identify patients at individual levels either in
this paper or in the database. Given the anonymous
and mandatory nature of the data, informed consent
was neither required nor necessary. The Spanish Minis-
try of Health evaluated the protocol of our investigation
and considered that it met all ethical aspects according
to Spanish legislation so provided us with the database.
The study was approved by the Research Ethic Com-
mittee of the Instituto de Salud Carlos III (ISCIII).
The MBDS provides the encrypted patient identifica-
tion number, sex, date of birth, dates of hospital admis-
sion and discharge, medical institutions providing the
services, the International Classification of Diseases,
9th ed, Clinical Modification (ICD-9-MC) codes of
diagnoses and procedures, and outcome at discharge.
In this study, HIV infection was assigned to patients
who had an ICD-9-CM code of 042 (HIV disease) or
V08 (Asymptomatic HIV infection status).
Exposure variables
We analyzed two kinds of exposure variables:
i.) HIV infection: we analyzed two study groups
according to HIV status: HIV-uninfected children
and HIV-infected children.
ii.) HAART, the standard treatment for HIV-infected
children: in this study, we divided the follow-up
period from 1997 to 2008 into three subperiods or
calendar periods, according to the widespread use of
HAART in children [21]: a) from 1997 to 1999
(1997–1999) for early-period HAART, b) from 2000
to 2002 (2000–2002) for mid-period HAART, and
c) from 2003 to 2008 (2003–2008) for late-
period HAART.
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Outcome variables
The index episode was defined as the occurrence of
a hospital discharge with candidiasis diagnosis via ICD-9
codes:
i.) Non-ICM: candidiasis of mouth (112.0), candidiasis
of vulva and vagina (112.1), candidiasis of other
urogenital sites (112.2), candidiasis of skin and nails
(112.3), candidal otitis external (112.82), candidal
esophagitis (112.84).
ii.) ICM: candidiasis of lung (112.4), disseminated
candidiasis (112.5), candidal endocarditis (112.81),
candidal meningitis (112.83), candidal enteritis
(112.85), other candidiasis of other specified sites
(112.89), candidiasis of unspecified site (112.9),
neonatal Candida infection (771.7).
Hospitalization was defined as a discharge record in
the MBDS, and children who were readmitted with
candidiasis in the same hospital and in the same calen-
dar year were counted as new diagnoses of candidiasis.
Estimation of the number of children living with HIV/AIDS
in Spain from 1997 to 2008
The estimation of the number of children living with
HIV/AIDS in Spain was made from two official registries
of HIV-infected children (see Additional file 1), as previ-
ously described [21]:
i. The number of HIV-infected children in the Madrid
cohort, which was supplied by the Madrid Cohort of
HIV Children (The Madrid HIV Paediatric Infection
Collaborative Study Group).
ii. The number of HIV-infected children with a
diagnosis of AIDS in Spain (AIDS-S), which was
supplied by the Spanish National AIDS Register
(National Centre for Epidemiology, Instituto de Salud
Carlos III,).
Statistical analysis
We calculated the rate or the number of events per 1,000
children-year, for overall and specific candidiasis diagno-
sis, according to each calendar period. The numerator was
Figure 1 Flow-chart for the selection of HIV-infected children (cases) and HIV-uninfected children (controls) under 17 years old and
candidiasis diagnosis in Spain from 1997 to 2008.
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the number of children and the number of candidiasis
diagnoses among HIV-infected children within each
period (whole follow-up or calendar period). The denom-
inator was different according to the type of rate calcu-
lated: a) for the events per 1,000 children with hospital
admission-year, we used number of HIV-uninfected chil-
dren or HIV-infected children with a hospital discharge
within the follow-up period (CMBD data); b) For the
events per 1,000 HIV-infected children-year, we used
the number of children living with HIV/AIDS in Spain
from 1997 to 2008 (see Additional file 1).
Candidiasis rates were compared using Poisson regres-
sion. Statistical analysis was performed using the R version
2.15.0 statistical package (GNU General Public License;
http://www.r-project.org/). All tests were two-tailed with
p-values <0.05 considered significant.
Results
Study population
Figure 1 shows the number of HIV-infected children
and HIV-uninfected children included in this study. We
included 1307 HIV-infected children with at least one
hospitalization episode. Of all these, 141 children had
149 candidiasis diagnoses, including 120 children with
128 non-ICM diagnoses and 21 children with ICM diag-
noses. In addition, we included a control group of 5228
randomly selected HIV-uninfected children with hospital
admissions matched by gender and age. Within the con-
trol group, 26 children had candidiasis diagnoses, includ-
ing 16 children with non-ICM diagnoses and 10 children
with ICM diagnoses.
Table 1 shows the epidemiological and clinical charac-
teristics of children with candidiasis diagnoses among the
cases (HIV-infected children) and controls (HIV-unin-
fected children) included in this study. When we analyzed
within cases and controls, HIV-uninfected children with
ICM diagnoses were older (p = 0.008), while HIV-infected
children with ICM diagnoses had longer hospital stays
(p = 0.049) than children with non-ICM diagnoses. Next,
we performed the analysis among diagnostics groups (All
candidiasis, non-ICM, and ICM). Overall, the percentage
of males was similar among groups, but HIV-infected chil-
dren were older (p = 0.016) and had longer hospital stays
(p = 0.006) than HIV-uninfected children. These trends
were maintained within non-ICM group. However, HIV-
infected children with ICM diagnosis had higher values
of percentage of males (p = 0.041) and length of stay (p <
0.001), but they had the lowest values of age (p < 0.001).
Candidiasis rates among children with hospital
admissions
Among children with hospital admissions, HIV-infected
children had a higher overall rate of candidiasis (events
per 1,000 children with hospital admission/year) than
HIV-uninfected children (107.0 versus 4.9; p < 0.001)
(Table 2). By type of candidiasis diagnosis, HIV-infected
children had higher rates of both non-ICM and ICM
diagnoses than HIV-uninfected children (91.8 versus 3.1
(p < 0.001) and 16.1 versus 1.9 (p < 0.001), respectively)
(Table 2). HIV-infected children also had higher rates of
non-ICM than ICM diagnoses (p < 0.001) (Table 2). The
most frequent diagnosis in both groups of children
(HIV-uninfected and HIV-infected children) was candid-
iasis of mouth.
When we divide the follow-up period into three separ-
ate calendar periods, we find that HIV-infected children
had much higher values than HIV-uninfected children
for overall candidiasis rates during each of the three pe-
riods (150.0 versus 6.1 (p < 0.001), 90.3 versus 3.1 (p <
0.001), and 79.3 versus 10.7 (p < 0.001), respectively) as
well as for non-ICM rates (118.5 versus 3.8 (p < 0.001),
85.3 versus 2.3 (p < 0.001), and 80.6 versus 6.0 (p <
0.001), respectively) (Table 3). HIV-infected children had
higher values of ICM rates than HIV-uninfected chil-
dren, however during the last calendar period no signifi-
cant difference was found (32.4 versus 1.2 (p < 0.001),
11.6 versus 0.4 (p < 0.001), and (4.6 versus 2.3 (p =
0.387), respectively) (Table 3). Of particular importance,
the rates of overall candidiasis, non-ICM, and ICM all
decreased from 1997–1999 to 2003–2008, however the
Table 1 Epidemiological and clinical characteristics of HIV-infected and HIV-uninfected children with candidiasis
diagnoses from 1997 to 2008















N 26 16 10 141 120 21
Males # 10 (38.5) 8 (50.0) 2 (20.0) 0.264 70 (49.6) 56 (46.7) 14 (66.7) 0.145 0.403 1 0.041
Age (years) * 0.5 (0; 8.7) 0 (0; 3.2) 9 (1.5; 11.0) 0.008 7 (1; 11) 7 (1; 11) 4 (2; 11) 0.921 0.016 <0.001 <0.001
Length of stay
(days) *
6.5 (3.2; 10.5) 5.5 (3.0; 7.5) 8.5 (7.0; 22.0) 0.125 13 (7; 22) 12 (7; 22) 18 (9; 42) 0.049 0.006 <0.001 <0.001
Values expressed as: (#) Absolute number (percentage); (*) Median (percentile 25; percentile 75).
Abbreviations: ICM, invasive candidiasis mycosis; HIV, Human immunodeficiency virus.
Significance level (p-values): (a), Non-ICM vs. ICM within a group; (b), all candidiasis between groups, (c); Non-ICM between groups, (d), ICM between groups.
Statistically significant differences are shown in bold.
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differences were only significant for HIV-infected chil-
dren with ICM diagnoses (p = 0.032).
Candidiasis rates among all children living with HIV/AIDS
During the follow-up period taken as a whole, the overall
rate of candidiasis in all HIV-infected children in Spain
(events per 1,000 HIV-infected children/year) was 11.3
(95% of confidence interval (95% CI): 9.5; 13.1), the non-
ICM rate was 9.7 (95% CI: 8.1; 11.4) and the ICM rate was
1.6 (95% CI: 0.9; 2.3).
When we divide the follow-up period into the three cal-
endar periods, the overall candidiasis rate decreased from
Table 2 Summary of the number and rates of children with candidias per 1,000 children with hospital admission/year
(bold font) and specific candidiasis diagnoses per 1,000 children with hospital admission/year (non-bold font) in HIV-
infected children and HIV-uninfected children in Spain from 1997 to 2008
HIV-uninfected children HIV-infected children
Description ICD-9 codex No. Rate (95% CI) No. Rate (95% CI)
All candidiasis 112.XX 26 5.0 (3.1; 6.9) 141 107.0 (90.1; 125.7) (*)
Non-invasive Candida mycosis (Non-ICM) 16 3.1 (1.6; 4.6) 120 91.8 (75.4; 108.3) (*, †)
Candidiasis of mouth 112.0 13 2.5 (1.1; 3.8) 104 79.6 (64.6; 94.7) (*)
Candidiasis of vulva and vagina 112.1 0 - 2 1.5 (0; 3.6)
Candidiasis of other urogenital sites 112.2 0 - 4 3.1 (0.1; 6.1)
Candidiasis of skin and nails 112.3 3 0.6 (0; 1.2) 5 3.8 (0.5; 7.2) (*)
Candidal otitis external 112.82 0 - 1 0.7 (0; 2.3)
Candidal esophagitis 112.84 0 - 12 9.2 (4.0; 14.4)
Invasive Candida mycosis (ICM) 10 1.9 (0.7, 3.1) 21 16.1 (9.2; 23.0) (*)
Disseminated candidiasis 112.5 1 0.2 (0; 0.6) 3 2.3 (0; 4.9) (*)
Candidal enteritis 112.85 0 - 5 3.8 (0.5; 7.2)
Other candidiasis of other specified sites 112.89 6 1.1 (0.2; 2.1) 7 5.3 (1.4; 9.3) (*)
Candidiasis of unspecified site 112.9 1 0.2 (0; 0. 6) 4 3.1 (0.1; 6.1) (*)
Neonatal candida infection 771.7 2 0.4 (0; 0.9) 2 1.5 (0; 3.6)
Abbreviations: ICM, invasive candidiasis mycosis; HIV, Human immunodeficiency virus; ICD-9, data are coded according to the International Classification of
Diseases (9th revision, Clinical Modification [ICD-9-MC]); Rate, events per 1,000 children with hospital admission/year; 95% CI, 95% of confidence interval.
(†): Significant differences between groups of study within a candidiasis diagnosis category (p < 0.001).
(*): Significant differences between Non-ICM and ICM categories within a study group (p < 0.001).
Table 3 Summary of the number and rates of children with candidiasis per 1,000 children with hospital admission/year
in HIV-infected children and HIV-uninfected children by calendar periods
1997-1999 2000-2002 2003-2008
Description No. Rate (95% CI) No. Rate (95% CI) No. Rate (95% CI)
All candidiasis
HIV-uninfected children 8 6.1 (1.9; 10.3) 4 3.1 (0.1; 6.1) 14 10.7 (5.1; 16.3)
HIV-infected children 64 150.0 (106.4; 175.5) 41 90.3 (62.7; 117.9) 36 79.3 (53.4; 105.2)
p-value <0.001 <0.001 <0.001
Non-invasive Candida mycosis (Non-ICM)
HIV-uninfected children 5 3.8 (0.5; 7.1) 3 2.3 (0; 4.8) 8 6.0 (1.8; 10.2)
HIV-infected children 50 118.5 (85.6; 151.3) 36 85.3 (57.4; 113.2) 34 80.6 (53.5; 107.6)
p-value <0.001 <0.001 <0.001
Invasive Candida mycosis (ICM)
HIV-uninfected children 3 1.2 (0; 2.5) 1 0.4 (0; 1.1) 6 2.3 (0.5; 4.2)
HIV-infected children 14 32.4 (15.4; 49.4) 5 11.6 (1.4; 21.7) 2 4.6 (0; 11.1)
p-value <0.001 <0.001 0.387
Abbreviations: ICM, invasive candidiasis mycosis; HIV, Human immunodeficiency virus; Rate, events per 1,000 children with hospital admission/yea; 95% CI, 95% of
confidence interval.
Statistically significant differences are shown in bold.
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1997–1999 to 2000–2002 (18.8 to 11.5; p < 0.001) and
from 2000–2002 to 2003–2008 (11.5 to 6.1; p = 0.060)
(Figure 2). Within each category of candidiasis, both non-
ICM and ICM rates had significant decreases from 1997–
1999 to 2003–2008 (14.7 to 5.6 (p < 0.001) and 4.1 to 0.3
(p < 0.001), respectively) (Figure 2). Finally, when we com-
pared the two categories of candidiasis diagnoses, the
non-ICM rates were higher than ICM rates throughout
the whole follow-up and within each calendar period
(Figure 2; p < 0.001).
Discussion
Other than for oral candidiasis, there is a scarcity of litera-
ture on the rate of candidiasis (invasive or non-invasive)
among HIV-infected children. This report is a retrospect-
ive study on an important part of follow-up of HIV-
infected children in Spain. In our study, HIV-infected
children were at increased risk of developing candidiasis
(ICM and non-ICM) compared to the general population,
but these rates, as with all opportunistic infections, de-
clined with the widespread use of HAART. In addition,
ICM was more infrequent than non-ICM among children
of the general population as well as among children with
HIV infection.
Poor cell-mediated immunity in HIV-infected children
often results in opportunistic infections, especially in ad-
vanced stages of HIV infection [11]. The candida species
is the most common cause of fungal infection among
HIV-infected children [16]. However, HAART-derived
immune reconstitution is an important protective factor
against candidiasis infection [19,20]. The recovery of cel-
lular immunity with HAART may partially reverse sus-
ceptibility to opportunistic infections when it achieves
sustained undetectable levels of HIV-RNA and CD4+
levels above 500 cells/mm3 over a long period of time
[9,11]. A high incidence of candidiasis diagnosis might be
due to the lack of complete immune reconstitution and
persistent CD4+ lymphopenia due to therapy failure [10].
The capacity of CD4+ recovery during long-term HAART
in HIV-infected children with CD4+ levels below 5% is
lower than in children with CD4+ levels from 5–15%, and
restoration of the CD4+ cell percentage to a normal level
is not necessarily achieved during long-term HAART [10].
Thus, continued surveillance of Candida infections may
be important in order to assess the long-term effect of
Figure 2 Summary of the epidemiologic trend of candidiasis (events per 1,000 HIV-infected children/year) among HIV-infected children
in Spain by calendar periods.
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HAART on the occurrence of opportunistic infections in
children.
Most candidiasis diagnoses were non-ICM and the
rate of non-ICM diagnoses was higher in HIV-infected
children than in HIV-uninfected children when children
with hospital admissions were compared. However, these
data should be interpreted with caution because they
refer to primary and secondary diagnoses among chil-
dren with hospital admissions. Since it is very rare for an
HIV-uninfected child to be admitted to a hospital because
of non-ICM such as oral candidiasis, the rate of non-ICM
in HIV-uninfected children may be underestimated, as the
database comes from hospital admissions only. Addi-
tionally, the rate of non-ICM children with hospital ad-
missions decreased during follow-up, but no significant
values were found. However, when we analyzed the data
by children living with HIV/AIDS, the non-ICM rate
decreased significantly in the last calendar period (2003–
2008), reaching values similar to those of other pediatric
populations infected with HIV [11,18,22]. This may be
due to the extensive use of HAART and improved immu-
nosurveillance, which is an important protective factor
against candidiasis [19,20]. In addition, advances in HIV
treatment, earlier diagnosis of infection status in exposed
infants, and quantitative monitoring of virology and im-
munologic parameters may also have contributed to de-
creases in candidiasis rates. Moreover, the earlier HIV
treatment starts over time, as per PENTA guidelines [23],
the more non-ICM will be prevented.
Most ICM in children occur in the hospital setting,
and this type of candidiasis is generally seen in severely
immunocompromised persons such as cancer, transplant
and AIDS patients, as well as nontrauma emergency sur-
gery and critical ICU patients [24]. ICM is a leading
cause of nosocomial mycosis with a high associated mor-
tality [17]. In our study, HIV-infected children with ICM
diagnoses had longer hospital stays than children with non-
ICM diagnoses, indicating that ICM diagnoses would ap-
pear in children with more serious clinical events and
suppressed immune systems [24]. Moreover, our data show
that HIV-infected children were at increased risk of devel-
oping ICM, although the ICM rate decreased during the
follow-up. Thus, ICM rate in the last calendar period
(2003–2008) was not higher in HIV-infected children than
in the general population according to our study and other
reports published [17,25,26]. Therefore, it is not as import-
ant of a health problem among HIV-infected children in
the last years of the HAART era.
This study had several limitations that may impact our
findings. This work was a retrospective study and we had
no access to patient clinical data (antiretroviral treatment
regimen, duration of HAART, CD4+ count, HIV viral
load, CDC stage) that might have affected our results.
MBDS data are anonymous and it is impossible to identify
whether a patient has been hospitalized at different hospi-
tals within the same calendar year. This may have caused
a slight overestimation of our results because we may have
calculated disease exacerbations or remissions as new par-
ticipants. We cannot know the total number of HIV-
infected children in Spain at present, because there is no
national coverage data of HIV diagnoses of children in
Spain. We used an estimation of the number of HIV-
infected children in Spain, which was calculated from two
reliable databases (Spanish National AIDS Register and
Madrid Cohort HIV Children).
Conclusions
Although the candidiasis rate still remains higher than
in the general population (from 1997 to 2008), candidia-
sis diagnoses decreased among HIV-infected children
throughout the HAART era and it has ceased to be a
major health problem among children with HIV infec-
tion in Spain.
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